Compagnie Lombard Odier SCmA Grows Holdings in DexCom, Inc. $DXCM

Compagnie Lombard Odier SCmA boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 18.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 216,798 shares of the medical device company’s stock after buying an additional 34,406 shares during the quarter. Compagnie Lombard Odier SCmA owned 0.06% of DexCom worth $14,389,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of DexCom during the second quarter worth about $26,000. SJS Investment Consulting Inc. lifted its stake in shares of DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after acquiring an additional 384 shares in the last quarter. Financial Consulate Inc. purchased a new position in DexCom in the third quarter valued at about $29,000. CVA Family Office LLC boosted its holdings in DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares during the last quarter. Finally, ORG Partners LLC grew its stake in DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several analyst reports. Barclays restated an “underweight” rating and set a $72.00 price objective (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Piper Sandler reissued an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Wells Fargo & Company dropped their price target on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $86.00 price target (up from $84.00) on shares of DexCom in a report on Friday, January 9th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a research note on Monday, January 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $86.50.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $64.85, for a total transaction of $110,245.00. Following the transaction, the executive vice president directly owned 112,904 shares in the company, valued at $7,321,824.40. This trade represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.32% of the stock is owned by company insiders.

DexCom Trading Down 0.7%

Shares of NASDAQ DXCM opened at $62.37 on Thursday. The stock’s 50 day moving average price is $69.56 and its two-hundred day moving average price is $67.34. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The stock has a market capitalization of $24.00 billion, a P/E ratio of 29.70, a PEG ratio of 1.22 and a beta of 1.55. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the business posted $0.45 EPS. DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. On average, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.